CGTX
Cognition Therapeutics Inc
$1.07
-0.01 (-0.93%)
At close · Jul 8
Market Cap
$95.76M
Shares
89,498,015
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.07
Open$1.06
Day$1.00–1.08
52W$0.52–3.83
Avg vol 30d2.0M
Short int7.5M · 8.4% float · 5.8d
Short vol65%
Last earningsMar 26, 2026
DataOct 2021–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−13%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−25%
trailing
YTD return
−21%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 75 funds reported for Jun 30 · net +6.7K sh shares
Insider flow
Accumulating
Net +$32.5K over 90 days · 0% sells
Short interest
Rising
8.39% of float · ▲ +16.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
75 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
EPS growth
+63%
Y/Y
Free cash flow
$-24.6M
Balance sheet
$36.8M
net cash
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
13.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 31, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 75 funds reported for Jun 30 · net +6.7K sh shares
Insider flow
Accumulating
Net +$32.5K over 90 days · 0% sells
Short interest
Rising
8.39% of float · ▲ +16.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
75 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 17%
52-wk high $4
vs 200-day avg -19%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGTX
this stock
Cognition Therapeutics Inc
|
$95.76M | -20.7% | — | — | 8.4% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGTX | -7.0% | -11.6% | -25.2% | -7.0% | -20.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -6.8% | -12.4% | -32.6% | -6.8% | -30.1% |